Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma
Yuqin Song(Peking University), Junyong Zhu(Peking University), Youngil Koh(Seoul National University), Dongmei Ji(Fudan University Shanghai Cancer Center), Hyeon‐Seok Eom(National Cancer Center), Junning Cao(Fudan University Shanghai Cancer Center), Jingrun Li(Capital Medical University), Mei Wang(Juntendo University), Jong-Seok Lee(Seoul National University Bundang Hospital), Haiyan Yang(Zhejiang Cancer Hospital), Jae‐Yong Kwak(Jeonbuk National University Hospital), Ho‐Jin Shin(Pusan National University Hospital), Dok-Hyun Yoon(Ulsan College), Won-Seog Kim(Samsung Medical Center), Jie Jin(First Affiliated Hospital Zhejiang University), Hongmei Jing(Institute of Deep-Sea Science and Engineering), Won-Sik Lee(Inje University Busan Paik Hospital)
Cited by 0
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
|Journal of Clinical Oncology|2022|375
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342